

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



深圳市海王英特龍生物技術股份有限公司
SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED*
(a joint stock limited company incorporated in the People's Republic of China)
(Stock Code: 8329)

(1) DELAY IN PUBLICATION OF AUDITED CONSOLIDATED ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2021 AND DESPATCH OF THE 2021 ANNUAL REPORT;
(2) PUBLICATION OF UNAUDITED CONSOLIDATED ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2021;
AND
(3) DATE OF BOARD MEETING

This announcement is made by Shenzhen Neptunus Interlong Bio-Technique Company Limited pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on the GEM of the Stock Exchange (the “**GEM Listing Rules**”) and the provisions of inside information under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).

Reference is made to the notice of the Company dated 21 March 2022 in relation to the meeting of the board (the “**Board**”) of directors (the “**Directors**”) of the Company to be held on 31 March 2022 to consider and approve, among other matters, the audited consolidated annual results of the Company and its subsidiaries (the “**Group**”) for the year ended 31 December 2021 (the “**2021 Audited Annual Results**”) and to approve the draft annual results announcement in respect of the audited consolidated annual results for publication.

DELAY IN PUBLICATION OF AUDITED CONSOLIDATED ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2021 AND DESPATCH OF THE 2021 ANNUAL REPORT

The Board hereby announces that, due to the recent COVID-19 outbreak in Hong Kong and the prevention and control measures of the COVID-19 in the People's Republic of China (the “**PRC**”), the audit process of the 2021 Audited Annual Results has been adversely affected as (i) travel restrictions and tightened measures for prevention and control of diseases have been enforced in the latest wave of the outbreak of COVID-19 in the PRC; (ii) there has been a delay in obtaining certain external confirmations from third parties for the audit; and (iii) the process of certain valuation work has been delayed.

Under Rule 18.49 and 18.48A of the GEM Listing Rules, the Company is required to publish the 2021 Audited Annual Results and despatch the annual report for the year ended 31 December 2021 (the “**2021 Annual Report**”) to the shareholders of the Company no later than 31 March 2022. Based on the information currently available to the Company, the Company estimates that the 2021 Audited Annual Results and the 2021 Annual Report will be published on or before 8 April 2022.

PUBLICATION OF UNAUDITED CONSOLIDATED ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2021

In order to keep the shareholders and potential investors of the Company informed of the Group’s business operation and financial position, the Board has decided to publish the unaudited consolidated annual results of the Group for the year ended 31 December 2021 (the “**2021 Unaudited Annual Results**”), which will have been reviewed by the audit committee of the Company but have not been agreed with the Company’s auditors, together with the audited comparable figures for the corresponding period in 2020, on 31 March 2022.

The Board will review and approve, among other things, the publication of the 2021 Unaudited Annual Results based on the management accounts of the Group for the year ended 31 December 2021.

DATE OF BOARD MEETING

The Board further announces that, a meeting of the Board is scheduled on Thursday, 31 March 2022 to consider and approve, among other matters, the publication of the 2021 Unaudited Annual Results.

As explained above, since the audit process has been delayed, the Board meeting originally scheduled to be held on Thursday, 31 March 2022 to consider and approve, among other matters, the 2021 Audited Annual Results, will be postponed to Friday, 8 April 2022.

The Company will keep the shareholders and potential investors of the Company informed of the development of the matter by making further announcement(s) as and when appropriate.

Shareholders and potential investors should exercise caution when dealing in shares of the Company.

By Order of the Board
Shenzhen Neptunus Interlong Bio-technique Company Limited*
Zhang Feng
Chairman

Shenzhen, the PRC, 28 March 2022

* *For identification purpose only*

As at the date of this announcement, the executive Directors are Mr. Zhang Feng and Mr. Huang Jian Bo; the non-executive Directors are Mr. Zhang Yi Fei, Ms. Yu Lin and Mr. Shen Da Kai; and the independent non-executive Directors are Mr. Yick Wing Fat, Simon, Mr. Poon Ka Yeung and Mr. Zhang Jian Zhou.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material aspects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least 7 days from its date of publication and on the Company’s website at www.interlong.com.